Annual Report and Form 20-F Information

The report records 2010 revenue of $33,269 million, with strong growth in key brands offsetting generic competition and weaker US sales. It describes the creation of a single R&D organization, medicine approvals, and annual benefits of $2.4 billion from the completed first phase of restructuring. The company reshaped its Responsible Business Plan and launched a new Safety, Health and Environment strategy. It met its waste and overall greenhouse-gas-footprint targets, while achieving a 9% reduction against a 12% target for emissions excluding those from respiratory therapies.